球后莎拉波娃與運動禁藥美度銨

Maria Sharapova and Meldonium Doping

10.6194/SCS.2016.42.12

張值維(Chih-Wei Chang)；陳昭彥(Chao-Yen Chen)；許美智(Mei-Chich Hsu)

美度銨 ； 代謝調節劑 ； Mildronate ； Meldonium ； metabolic modulators ； Mildronate

運動教練科學

42期（2016 / 06 / 01）

121 - 130

繁體中文

網球運動員莎拉波娃（Maria Sharapova）是全球最知名且富有的女性運動員之一，莎拉波娃未通過2016 年澳網禁藥檢驗，她承認服用美度銨（Meldonium）治療心臟疾病有10 年之久，此事件將可能使她面臨至少禁賽2 年之處分。美度銨是列於世界運動禁藥管制機構（World Anti-Doping Agency, WADA）發布的2015 年監視中藥物的名單中，而2016 年則列入荷爾蒙及代謝調節劑運動禁藥，WADA 公布自2016 年起已有至少99 件美度銨陽性反應紀錄。美度銨未經臺灣與美國的食品藥物管理單位核准，因此，大部分陽性紀錄出現在歐洲運動員，仿單指示可用於治療穩定型心絞痛、慢性心衰竭等心血管疾病、急慢性腦缺血、顱腦損傷後恢復、身心理疾病等，美度銨被認為具有提升運動表現的潛力，將破壞比賽公平性。本文將介紹美度銨的臨床用途、作用機轉，並探討尿液檢驗與運動員使用美度銨陽性案例的情形及如何避免違規使用到運動禁藥。

Tennis player Maria Sharapova is one of the most famous and richest female athlete in the world; however, she did not pass the doping test in 2016 Australian Open. Sharapova had admitted taking Meldonium to treat heart disease for 10 years. She will probably receive the punishment for at least 2-year suspension. Meldonium was listed in the monitoring program by World Anti-Doping Agency (WADA) in 2015, whereas it is currently included in hormones and metabolic modulators of the prohibited substances in 2016. WADA has announced that there are at least 99 positive cases for Meldonium doping since 2016. Taiwan and United States Food and Drug Administration do not approve Meldonium on the markets. Therefore, the majority of positive cases for Meldonium doping existed in European players. The indications for Meldonium include stable angina, chronic heart failure and other cardiovascular diseases, acute and chronic brain ischemia, traumatic brain recovery after injury, physical and mental illness. Meldonium is considered to potentially enhancing athletic performance, which will result in unfair competition. This article describes the clinical use of Meldonium, the mechanism of actions, the urine analysis, positive cases for Meldonium doping in athletes, and how to avoid illegal use of doping.

1. World Anti-Doping Agency. (2015b). World antidoping code. Retrieved May 3, 2016, from https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2015-world-anti-dopingcode.pdf
2. Grindex. (2012). ZĀĻU APRAKSTS of MILDRONĀTS®. Retrieved May 3, 2016, from http://www.grindeks.lv/mce/uploads/tmceimages/Mildr.250_500%20kaps.5SPC%20LV_kludas%20lab_07.06.12.pdf
3. World Anti-Doping Agency. (2016). Meldonium notice. Retrieved May 3, 2016, from https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2016-04-12-Meldonium-notice-en.pdf
4. Newsweek. (2016). 99 Meldonium positive tests recorded since January 1 ban: World antidoping agency. Retrieved May 3, 2016, from http://www.newsweek.com/Meldonium-mariasharapova-wada-doping-435992
5. World Anti-Doping Agency. (2014). The 2015 prohibited list: International standard. Retrieved May 3, 2016, from https://wadamain-prod.s3.amazonaws.com/resources/files/wada-2015-prohibited-list-en.pdf
6. World Anti-Doping Agency. (2015a). The 2016 prohibited list: International standard. Retrieved May 3, 2016, from https://wadamain-prod.s3.amazonaws.com/resources/files/wada-2016-prohibited-list-en.pdf
7. Dambrova, M.,Makrecka-Kuka, M.,Vilskersts, R.,Makarova, E.,Kuka, J.,Liepinsh, E.(2016).Pharmacological effects of Meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.Pharmacological Research
8. Dudko, V. A.,Koshel'skaia, O. A.,Sokolov, A. A.(1989).The use of mildronat with stenocardia patients.Vrachebnoe Delo,10,64-67.
9. Dzerve, V.,Matisone, D.,Kukulis, I.,Romanova, J.,Putane, L.,Grabauskienė, V.(2005).Mildronate improves peripheral circulation in patients with chronic heart failure: Results of clinical trial (the first report).Seminars in Cardiology,11(2),56-64.
10. Dzerve, V.,Matisone, D.,Pozdnyakov, Y.,Oganov, R.(2010).Mildronate improves the exercise tolerance in patients with stable angina: Results of a long term clinical trial.Seminars in Cardiovascular Medicine,16(3)
11. Dzerve, V.,MILSS I Study Group(2011).A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: A clinical trial "MILSS I".Medicina,47(10),544-551.
12. Dziak, L. A.,Golik, V. A.(2003).Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head.Likars'ka Sprava,5-6,98-101.
13. Dzintare, M.,Kalvins, I.(2012).Mildronate increases aerobic capabilities of athletes through carnitine-lowering effect.5th Baltic Sports Science Conference,Kaunas, Lithuania:
14. Görgens, C.,Guddat, S.,Dib, J.,Geyer, H.,Schanzer, W.,Thevis, M.(2015).Mildronate (Meldonium) in professional sports -Monitoring doping control urine samples using hydrophilic interaction liquid chromatography- High resolution/high accuracy mass spectrometry.Drug Testing and Analysis,7(11-12),973-979.
15. Kukes, V. G.,Zhernakova, N. I.,Gorbach, T. V.,Romashchenko, O. V.,Rumbesht, V. V.(2013).Efficiency of mildronate in rats of different age with experimental-induced myocardial ischemia.Vestnik Rossiĭskoĭ Akademii Meditsinskikh Nauk,68(1),42-46.
16. Liepinsh, E.,Dambrova, M.(2016).The unusual pharmacokinetics of meldonium: Implications for doping.Pharmacological Research,111,100.
17. Liepinsh, E.,Konrade, I.,Skapare, E.,Pugovics, O.,Grinberga, S.,Kuka, J.(2011).Mildronate treatment alters γ-butyrobetaine and L-carnitine concentrations in healthy volunteers.Journal of Pharmacy and Pharmacology,63(9),1195-1201.
18. Makrecka, M.,Svalbe, B.,Volska, K.,Sevostjanovs, E.,Liepins, J.,Grinberga, S.(2014).Mildronate, the inhibitor of L-carnitine transport, induces brain mitochondrial uncoupling and protects against anoxia-reoxygenation.European Journal of Pharmacology,723,55-61.
19. Ol'binskaia, L. I.,Golokolenova, G. M.(1990).Use of mindronate in cardiac insufficiency in patients with ischemic heart disease.Klinicheskaia Meditsina,68(1),39-42.
20. Sjakste, N.,Gutcaits, A.,Kalvinsh, I.(2005).Mildronate: An antiischemic drug for neurological indications.CNS Drug Reviews,11(2),151-168.
21. Spasov, A. A.,Kovalev, G. V.,Tsibanev, A. V.(1990).Method of studying the effects of pharmacological substances on work capacity of animals in hypobaric hypoxia.Biulleten' Eksperimental'noĭ Biologii i Meditsiny,110(8),164-166.
22. Teplyakov, A. T.,Sankevitch, T. V.,Stepatcheva, T. A.,Mamchur, S. E.(2003).The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction.Kardiologiia,43(12),15-18.
23. Vitols, A.,Voita, D.,Dzerve, V.(2008).Mildronate improves carotid baroreceptor reflex function in patients with chronic heart failure.Seminars in Cardiovascular Medicine,13(7)
24. Wells, B. G.,DiPiro, J. T.,Schwinghammer, T. L.,DiPiro, C. V.(2015).Pharmacotherapy handbook.New York:McGraw-Hill Education.
25. Zhang, J.,Cai, L. J.,Yang, J.,Zhang, Q. Z.,Peng, W. X.(2013).Nonlinear pharmacokinetic properties of mildronate capsules: A randomized, open-label, single- and multipledose study in healthy volunteers.Fundamental & Clinical Pharmacology,27(1),120-128.
26. Zhu, Y.,Zhang, G.,Zhao, J.,Li, D.,Yan, X.,Liu, J.(2013).Efficacy and safety of mildronate for acute ischemic stroke: A randomized, double-blind, active-controlled phase II multicenter trial.Clinical Drug Investigation,33(10),755-760.

1. 陳昭彥、許美智、張值維(2016)。列管於運動禁藥監控計畫中的Telmisartan。運動生理暨體能學報，23，13-22。
2. 許美智,張值維,林逸茜,吳育澤,王致遠(2023)。臺灣「運動禁藥查詢系統」行動應用程式之開發與進展。臺灣體育學術研究，74，123-133。
3. 劉曉蓉,陳靜如,張博能,林逸茜,何健章(2020)。大專運動員對「運動禁藥查詢系統App」的使用動機與滿意度。大專體育，152，40-48。